Revolution Medicines specializes in developing precision oncology therapies, particularly RAS(ON) inhibitors and RAS Companion inhibitors, with their lead product candidate, RMC-4630, currently in a Phase 1/2 clinical program targeting specific oncogenic mutations in various tumor types. The company's main focus is on developing these therapies to target specific oncogenic mutations in different tumor types, utilizing precision oncology technologies.